新穎奈米果糖脂肪酸酯作為抗菌/抗內毒素之精準醫療標靶及其生技產業應用

Sepsis is a systemic inflammatory state in response to infection, and concomitant acute kidney injury (AKI) increases mortality significantly. However, severe sepsis induced AKI cannot be efficiently prevented and cured by current antimicrobial therapies and supportive measures. To effectively prevent and treat sepsis-related syndromes, this project is designed to develop lipase esterification of fructose with fatty acids and obtain several types of fructose monoesters or diesters. Our preliminary data show that the use of surface plasmon resonance, cyclic voltammetry and ultrasensitive chemiluminscence analyzer evidence the bacterial growth inhibition, the LPS/endotoxin binding and a strong antioxidant activity. On the other hand, to prevent the adverse effect by the lysis fructose ester product, fructose, induced metabolic syndrome and fatty liver, we have tried to use rat intestinal acetone powder to digest these fructose esters and determine the stability of these fructose esters. Our preliminary data showed that our established fructose esters are not easily hydrolyzed by the rat intestinal acetone powder implicating its stability in the gastrointestinal tract. Therefore, these results of the project will establish an enzymatic preparation and technique of fructose esters of fatty acids for mass production in the industry and their potential application in medical drugs, materials and functional foods. In the three-year project, we will develop novel, effective and safe nanoparticles of D-fructose esters of fatty acids to confer precision medicine target to bacterial growth inhibition and endotoxin absorption/neutralization. The developed and mass produced nanoparticles of fructose esters will be applied to prevent and treat sepsis-induced AKI. We will finish the following targets within three years: (1) to identify and verify the damaged or protective biomarker from the whole kidney non-coding RNA of the sepsis-induced acute kidney injury by the next generation sequence technique, (2) to decrease the occurred frequency and severity of the sepsis-induced acute kidney injury, (3) to explore the possibility of D-fructose esters derivatives being a non-antibiotics adjuvants on Helico pylori growth inhibition, (4) to be a new and safe sweetener to reduce and/or prevent D-fructose induced metabolic syndrome and possible tumorigenesis, and (5) using D-fructose esters as a medical material to establish a new patent of a device to adsorb endotoxin/lipopolysaccharide.